Andere Sprachen Vivesto AB

Aktien

509722

SE0000722365

VIVE

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:38 10.05.2024			% 5 Tage	% 1. Jan.
0,307 ^SEK	+1,32 %		+0,33 %	-24,66 %

26.03.	Transcript : Vivesto AB - Special Call
07.03.	Vivesto AB verabreicht den ersten Patienten in seiner klinischen Paccal Vet Studie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Notice of Annual General Meeting in Vivesto AB	23.04.
Vivesto to hold live-streamed Paccal Vet R&D Update on March 26	19.03.
Vivesto doses first patient in its clinical Paccal Vet trial	07.03.
Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial	07.03.
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Vivesto's international patent application for XR-18 receives positive decision	30.01.
Vivesto's International Patent Application for XR-18 Receives Positive Decision	30.01.
Vivesto Gains on Receipt of US Approval for Pilot Clinical Trial of Drug Candidate Paccal Vet	28.12.
Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment	28.12.
Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment	28.12.
Vivesto’s Paccal Vet granted FDA MUMS designation	22.12.
Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea	22.12.
Vivesto AB Reports Positive Preclinical Data Supporting Continued Development of Cantrixil	19.12.
Vivesto reports positive preclinical data supporting continued development of Cantrixil	19.12.
Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto	23.11.
Vivesto AB Announces Composition of Nomination Committee	23.11.
Vivesto Abandons Apealea Partnership with Elevar Therapeutics	23.11.
Vivesto and Elevar sign agreement ending Apealea® partnership	23.11.
Vivesto AB and Elevar Therapeutics Inc. Sign Agreement Ending Apealea®? Partnership	23.11.
Interim report for the period January 1, 2023 – September 30, 2023	16.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vivesto AB

Aktien

509722

SE0000722365

VIVE

Andere Sprachen

Filter